Clene Inc. Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount
Clene Inc. (CLNN) reported Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount of $398.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Notes › Income Taxes
us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount · last filed 2026-03-17
- Clene Inc. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2025 was $398.00K, a 7.01% decline from fiscal 2024.
- Clene Inc. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2024 was $428.00K, a 0.70% decline from fiscal 2023.
- Clene Inc. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2023 was $431.00K.
- Clene Inc. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2022 was -$170.00K.
| Period end | Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount 12 month |
|---|---|
| 2025-12-31 | $398.00K 10-K · filed 2026-03-17 |
| 2024-12-31 | $428.00K 10-K · filed 2026-03-17 |
| 2023-12-31 | $431.00K 10-K · filed 2025-03-24 |
| 2022-12-31 | -$170.00K 10-K · filed 2024-03-13 |
| 2021-12-31 | -$462.00K 10-K · filed 2023-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |